NASDAQ$APLS
Apellis Pharmaceuticals Inc. · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Apellis reported second quarter 2023 financial results, featuring strong SYFOVRE launch and continued momentum in PNH.
Apellis Pharmaceuticals reported a total revenue of $95.0 million for Q2 2023, driven by $67.3 million from SYFOVRE and $22.3 million from EMPAVELI. The company's cash and cash equivalents stood at $616.3 million as of June 30, 2023. A comprehensive investigation found no indication of drug product or manufacturing issues contributing to the rare events of retinal vasculitis with SYFOVRE.
- Total U.S. net product revenues reached $89.6 million, with SYFOVRE contributing $67.3 million and EMPAVELI $22.3 million.
- SYFOVRE demonstrated a reduction of up to 45% in nonsubfoveal GA lesion growth between Months 24-30 in the GALE long-term extension study.
- Investigation into rare safety events with SYFOVRE found no indication of drug product or manufacturing issues.
- Cash and cash equivalents totaled $616.3 million as of June 30, 2023.
Headline financials
Revenue & EPS history
Apellis · Revenue · Quarterly
$95M
Revenue by segment
Apellis · $94.9M total across 3 segments · Q2 2023
- SYFOVRE U.S. Net Product Revenue$67.3M—70.9%
- EMPAVELI U.S. Net Product Revenue$22.3M—23.5%
- Licensing and Other Revenue$5.32M+697.0%5.6%
Forward guidance
Apellis anticipates its cash balance, combined with cash anticipated to be generated from sales of EMPAVELI and SYFOVRE and Sobi reimbursements, to fund operations into the first quarter of 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2023
-0.7%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+6.0%
Avg return
30 days after
43%
15 / 35 earnings
Positive
+18.6%
Q4 2022
Best reaction
-24.4%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.3% | -0.1% | — | |
| Q4 2025 | -3.8% | -6.7% | -21.5% | |
| Q3 2025 | -1.0% | -6.9% | +7.2% | |
| Q2 2025 | +17.5% | +27.4% | +45.1% | |
| Q1 2025 | -5.8% | -8.4% | +0.8% | |
| Q4 2024 | -3.3% | +0.0% | -6.7% | |
| Q3 2024 | +0.9% | +5.0% | +17.1% | |
| Q2 2024 | -7.7% | -11.3% | -1.8% | |
| Q1 2024 | -13.3% | -14.0% | -15.9% | |
| Q4 2023 | -10.7% | -10.9% | -18.1% | |
| Q3 2023 | +1.4% | -6.6% | +26.6% | |
| Q2 2023 | -24.4% | -23.4% | +26.8% | |
| Q1 2023 | +9.6% | +5.2% | +3.5% | |
| Q4 2022 | +18.6% | +20.2% | +13.9% | |
| Q3 2022 | -6.6% | -10.5% | -5.8% | |
| Q2 2022 | +1.5% | +7.3% | +1.5% | |
| Q1 2022 | -0.1% | -17.6% | +2.1% | |
| Q4 2021 | +5.2% | +2.3% | +16.3% | |
| Q3 2021 | +9.3% | +27.4% | +25.9% | |
| Q2 2021 | -5.6% | -9.3% | -12.3% | |
| Q1 2021 | +6.1% | +10.5% | +23.8% | |
| Q4 2020 | +4.3% | -1.3% | -10.2% | |
| Q3 2020 | +4.9% | +12.9% | +42.4% | |
| Q2 2020 | -0.7% | -2.5% | -3.8% | |
| Q1 2020 | -6.1% | -6.6% | -7.7% | |
| Q4 2019 | +0.5% | +5.0% | -23.8% | |
| Q3 2019 | +0.1% | -2.5% | -15.6% | |
| Q2 2019 | -2.8% | -12.5% | +0.8% | |
| Q1 2019 | +1.0% | -3.2% | +12.9% | |
| Q4 2018 | -4.8% | +22.4% | +27.5% | |
| Q3 2018 | -7.3% | +2.4% | +26.9% | |
| Q2 2018 | -3.9% | -4.3% | +8.1% | |
| Q1 2018 | -8.6% | -1.8% | -16.7% | |
| Q4 2017 | -5.6% | -5.8% | +1.3% | |
| Q3 2017 | +15.3% | +28.3% | +31.4% | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro